• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Liquidia Corporation - Common Stock (NQ:LQDA)

    30.26 -40.43 (-57.19%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Liquidia Corporation - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Top movers analysis one hour before the close of the markets on 2026-09-30: top gainers and losers in today's session. ↗
    Via Chartmill
    Let's take a look at the stocks that are in motion in today's session. ↗
    Via Chartmill
    Liquidia (NASDAQ:LQDA) High Growth Momentum Meets a Pre-Breakout Setup ↗
    Via Chartmill
    Liquidia (NASDAQ:LQDA): Strong Growth Paired With Technical Setup Quality ↗
    Via Chartmill
    LIQUIDIA CORP (NASDAQ:LQDA) Fits the Affordable Growth Screen ↗
    Via Chartmill
    News headline image
    Liquidia (LQDA) Q2 2026 Earnings Call Transcript ↗
    YUTREPIA sales hit $170.4 million with 5,000+ patients started on therapy. 
    Via The Motley Fool
    Topics Earnings
    Liquidia Corp (NASDAQ:LQDA) Shows High Growth Momentum With a Breakout Setup ↗
    Via Chartmill
    LIQUIDIA CORP (NASDAQ:LQDA): A High Growth Stock with a Strong Technical Setup ↗
    Via Chartmill
    News headline image
    Why Liquidia Stock Was Diving This Week ↗
    It needed to post a blowout quarter instead of the good one it delivered. 
    Via The Motley Fool
    News headline image
    Liquidia Q2 Earnings Call Highlights ↗
    Liquidia (NASDAQ:LQDA) reported second-quarter 2026 results marked by continued growth for its inhaled treprostinil product YUTREPIA, increased profitability and expanding investment in its clinical... 
    Via MarketBeat
    Topics Earnings
    Liquidia Corp (NASDAQ:LQDA): An Affordable Growth Stock With Explosive Revenue Momentum and Reasonable Forward Valuation ↗
    Via Chartmill
    News headline image
    Transcript: Liquidia Q1 2026 Earnings Conference Call ↗
    Liquidia (NASDAQ:LQDA) released first-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call... 
    Via Benzinga
    Topics Earnings
    Liquidia Corp. (NASDAQ:LQDA) Flashes Perfect 10/10 Technical Score on Minervini Trend Template and High Growth Momentum ↗
    Via Chartmill
    Liquidia Corp (NASDAQ:LQDA): Affordable Growth Play With Explosive Revenue ↗
    Via Chartmill
    Liquidia Corp (NASDAQ:LQDA) Smashes Q1 Estimates as YUTREPIA Adoption Accelerates ↗
    Via Chartmill
    Liquidia Corp (NASDAQ:LQDA): High Growth Momentum Setup Nears Breakout ↗
    Via Chartmill
    Liquidia Corp (NASDAQ:LQDA) Presents a High-Growth Momentum and Technical Setup ↗
    Via Chartmill
    News headline image
    What to Know About This Fund’s $15.5 Million Sale of Liquidia as Shares Skyrocket Nearly 260% ↗
    Liquidia develops therapies for rare cardiopulmonary diseases, leveraging proprietary drug delivery technologies in the U.S. market. 
    Via The Motley Fool
    News headline image
    Liquidia (LQDA) Q1 2026 Earnings Transcript ↗
    Liquidia (LQDA) Q1 2026 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Liquidia Q1 Earnings Call Highlights ↗
    Liquidia (NASDAQ:LQDA) reported sharply higher first-quarter 2026 sales and profitability as executives said the launch of YUTREPIA continued to gain traction in pulmonary arterial hypertension and... 
    Via MarketBeat
    Topics Earnings
    Liquidia Corp (NASDAQ:LQDA) Shows High-Growth Momentum and Minervini Trend Alignment ↗
    Via Chartmill
    Liquidia Corp (NASDAQ:LQDA) Reports Q4 2025 Profitability and Revenue Beat Driven by YUTREPIA Launch ↗
    Via Chartmill
    News headline image
    This Biotech Stock Has Soared 175%. Here’s Why One Fund Still Sold $3 Million Worth ↗
    This biotech firm develops therapies for rare pulmonary diseases, leveraging proprietary drug delivery technology in the U.S. market. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Liquidia's (LQDA) CEO Sells 53,000 Shares for $2.1 Million ↗
    Biotech innovator Liquidia, specializing in pulmonary therapies, reported a notable insider sale amid continued growth in its core market. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Liquidia's Chairman Sold Company Shares Worth $2.5 Million. Should Investors Avoid the Stock? ↗
    This biotech focused on pulmonary therapies reported a notable insider sale amid strong share price gains and rising revenue. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    The Chief Commercial Officer of Liquidia (LQDA) Sold 80,000 Shares for $2.8M ↗
    Biotech innovator Liquidia, focused on therapies for rare conditions, reported a notable insider sale amid strong recent share performance. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Liquidia Stock Up 135% as Insider Sells $1.3 Million in Shares ↗
    This biotech innovator in rare disease therapies reported significant insider selling amid a year of robust stock performance. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Dave Stock Soars 150% in a Year as Newly Disclosed $7 Million Buy Signals Confidence in Fintech Upstart ↗
    Dave Inc. delivers digital banking and personal finance tools designed to offer alternatives to traditional banking platforms. 
    Via The Motley Fool
    Topics ETFs
    News headline image
    Liquidia (LQDA) Q4 2025 Earnings Call Transcript ↗
    Liquidia (LQDA) Q4 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Liquidia Stock Gains Premarket On Q4 Revenue Beat – Investors Are Betting On YUTREPIA Growth ↗
    Product revenue from YUTREPIA reached approximately $148.3 million in 2025, including about $90.1 million generated during the fourth quarter alone. 
    Via Stocktwits
    Topics Artificial Intelligence
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.